Switzerland’s Schweizerhall says that its generic version of the blockbuster bloodthinner Plavix can now be marketed in Germany after a court there rejected an appeal by Sanofi-Aventis.

Schweizerhall's Cimex unit had already received final approval from the German regulator BfArM to sell its copycat version of Plavix (clopidogrel) and transferred that approval to its marketing partners (Novartis’ Sandoz unit and Ratiopharm). This was then followed by a challenge to the decision by Sanofi.

However the next stage in the saga saw the German administrative court in Cologne last week order immediate enforcement of marketing authorisations granted in the country for generic versions of the drug, a move Sanofi acted swiftly open. The French drugmaker appealed to the German higher administrative court in Muenster against the ruling of the Cologne court and requested a temporary suspension of the immediate execution of the approval.

That bid has ended in failure, according to Schweizerhall, which said that the Muenster court dismissed the appeal last Friday. This ruling has cleared the way for the partners of Cimex to start marketing generic clopidogrel in Germany but Schweizerhall could not confirm to PharmaTimes World News any details about a possible launch.